The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000417381
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
16/10/2025
Date registered
Help: Date registered
7/04/2026
Date last updated
Help: Date last updated
11/11/2026
Date data sharing statement initially provided
Help: Data sharing statement date
7/04/2026
Type of registration
Help: Type of registration
Retrospectively registered

Titles & IDs
Public title
A Phase 2, Randomized, Observer-Blind, Dose Finding Trial to Evaluate Safety and Immunogenicity of an Investigational Pandemic Flu Vaccine
Scientific title
A Phase 2, Randomized, Observer-Blind, Dose Finding Trial to Evaluate Safety and Immunogenicity of 1 and 2 Administrations of Pandemic Monovalent Influenza Vaccines Administered at Different Antigen and Adjuvant (CpG 1018®Adjuvant and Alum) Doses
Additional trial identifiers [1] 315093 0
VCH26709
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Influenza 338492 0
Condition category
Condition code
Infection 334797 334797 0 0
Other infectious diseases

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Two age cohorts will be randomised as part of part 2 (18-64 and greater than or equal to 65 years old) into 5 arms per cohort receiving a singular intramuscular injection of A/H5N1 HA with CpG 1018® Adjuvant with or without alum on Day 1
Doses for both age cohorts in the phase 2 study will be determined based on results from phase 1
1: HA 15 mcg; alum 750 mcg
2: HA 15 mcg; CpG 1018 750 mcg; alum 750 mcg
3: HA 7.5 mcg; CpG 1018 750 mcg; alum 750 mcg
4: HA 3.75 mcg; CpG 1018 750 mcg; alum 750 mcg
5: HA 15 mcg; CpG 1018 3000 mcg; alum 750 mcg
21 days after initial administration patients will either receive a second, single dose of the investigational product or a placebo, 1mL normal saline based on randomisation at enrollment. Participants in Arm 5 will receive placebo as the second injection.
Product was administered at the study site so adherence to the assigned study arm was captured in site records.


Intervention code [1] 331708 0
Prevention
Description of the comparator or control
Comparator for both age cohorts is Dose group 1 of both cohorts (HA 15 mcg; alum 750 mcg) against which dose groups (2-5) will be compared
Control group
Active

Outcomes
Primary outcome [1] 342433 0
To assess humoral immunogenicity for selected doses/formulations of A/H5N1 antigen, CpG 1018 Adjuvant (and alum, if applicable) 21 days after final trial injection in participants
Timepoint [1] 342433 0
21 days after second trial injection
Secondary outcome [1] 450801 0
To assess humoral immunogenicity for selected doses of A/A/H5N1 antigen, CpG 1018, and alum (if applicable) at multiple timepoints in participants at selected timepoints
Timepoint [1] 450801 0
21 days after first trial injection and 6 months after final trial injection:
Secondary outcome [2] 450802 0
To evaluate the safety of H5N1 antigen + CpG 1018 +/- alum (DC01)
Timepoint [2] 450802 0
7 days following each dose
Secondary outcome [3] 450803 0
To evaluate the safety of H5N1 antigen + CpG 1018 +/- alum (DC01)
Timepoint [3] 450803 0
21 days following each dose using the following, The Grading Scale for AE in the CBER Guidance on Toxicity Grading for Healthy Volunteers in Vaccine Clinical Trials and the Solicited Post-Injection Reaction Grading Scale adapted from the Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials.
Secondary outcome [4] 450804 0
To evaluate the safety of H5N1 antigen + CpG 1018 +/- alum (DC01)
Timepoint [4] 450804 0
Day 1 through 6 months using The Grading Scale for AE in the CBER Guidance on Toxicity Grading for Healthy Volunteers in Vaccine Clinical Trials and the Solicited Post-Injection Reaction Grading Scale adapted from the Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials.

Eligibility
Key inclusion criteria
1) Willing to participate: informed consent provided for the trial
2) Male and female participants greater than or equal to 18 to 64 years of age (Age cohort 1) and greater than or equal to 65 years of age (Age cohort 2)
3) Be in good health in the opinion of the investigator, based upon medical history, physical examination and laboratory evaluation
4) Must be able to comprehend and follow all required trial procedures and be available for all visits scheduled in the trial
5) Seronegative for human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV)
6) If female of child-bearing potential and heterosexually active, has practiced adequate contraception for at least 28 days prior to vaccination, has negative pregnancy tests just prior to vaccination, and has agreed to continue adequate contraception through 3 months following the final study injection.
7) A premenopausal woman who has at least one of the following is considered not of childbearing potential:
a) Documented hysterectomy
b) Documented bilateral salpingectomy
c) Documented bilateral oophorectomy
d) Documented and current bilateral tubal ligation or occlusion
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
Yes
Key exclusion criteria
1) History of sensitivity to any component of trial vaccine(s)
2) Recent or ongoing history of febrile illness within 72 hours of the trial injection (defined as at least 1 measured body temperature of greater than or equal to 38°C, regardless of route of measurement). Participants meeting this criterion may be rescheduled within the protocol-defined window.
3) If female, is pregnant (known before or established at the time of screening), breastfeeding, or planning a pregnancy or to breastfeed
4) Known or suspected immunodeficiency (including but not limited to HIV/AIDS), or immunocompromised state, as assessed by medical history, past or current laboratory studies, and/or physical examination
5) Has received the following prior to any trial injection:
a) within 14 days:
i) Any licensed or authorized inactivated vaccines (including vaccines containing mRNA or CpG)
b) within 28 days:
i) Any live vaccine
ii) Any other investigational medicinal agent
c) within 90 days:
i) Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune modifying drugs during the period starting 90 days prior to the first study vaccine administration or planned administration during the study period. (For corticosteroids, this will mean prednisone greater than or equal to 20mg/day, or equivalent.
Inhaled, topical, and intraarticular steroids, other topical immunomodulators, and imiquimod are allowed.)
ii)Granulocyte or granulocyte-macrophage colony-stimulating factor
iii) Immunoglobulins or any blood products (receipt of certain monoclonal antibodies may on a case-by case basis be non-exclusionary if approved via consultation with Sponsor Medical Monitor)
iv) Antisense oligonucleotides
v) Drugs/investigational agents with very long half-lives (defined as greater than equal to 60 days)
vi) Infusion of blood products
d) At any time: DNA plasmids or other genetic therapy intended to integrate permanently into host cell
6) Is undergoing chemotherapy or expected to receive chemotherapy during the trial period; has a diagnosis of cancer within the last 5 years other than squamous cell or basal cell carcinoma of the skin
7) History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the participant's participation for the full duration of the trial, or is not in the best interest of the participant to participate, in the opinion of the treating investigator.
8) Underlying chronic medical condition requiring ongoing followup and monitoring by a healthcare provider that might affect the immune response to vaccine (eg, diabetes mellitus, chronic kidney disease)
9) Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
10) Current or historical autoimmune disease
11) Any skin condition and/or tattoo on both arms that may interfere with the evaluation of safety at the injection site.
12) Any other finding that the Investigator considers will make the participant unsuitable for the trial or unable to comply with the trial requirements



Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Central randomisation by computer
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation using a randomisation table created by computer software (i.e. computerised sequence generation)
Masking / blinding
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
ACT,NSW,QLD,VIC

Funding & Sponsors
Funding source category [1] 319664 0
Commercial sector/Industry
Name [1] 319664 0
Dynavax Technologies Corporation
Country [1] 319664 0
United States of America
Primary sponsor type
Commercial sector/Industry
Name
PPD Australia PTY LTD
Address
Country
Australia
Secondary sponsor category [1] 322167 0
None
Name [1] 322167 0
Address [1] 322167 0
Country [1] 322167 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 318228 0
Bellberry Human Research Ethics Committee K
Ethics committee address [1] 318228 0
Ethics committee country [1] 318228 0
Australia
Date submitted for ethics approval [1] 318228 0
09/12/2024
Approval date [1] 318228 0
24/02/2025
Ethics approval number [1] 318228 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 143502 0
Dr Paul Nguyen
Address 143502 0
Emeritus Research, 1096 Toorak Rd, Camberwell, 3124, VIC
Country 143502 0
Australia
Phone 143502 0
+61 3 9509 6166
Fax 143502 0
Email 143502 0
Contact person for public queries
Name 143503 0
Trial Transparency
Address 143503 0
1 Discovery Drive, Swiftwater, PA, 18370
Country 143503 0
United States of America
Phone 143503 0
+1 8006331610
Fax 143503 0
Email 143503 0
[email protected] (preferred)
Contact person for scientific queries
Name 143504 0
Trial Transparency
Address 143504 0
1 Discovery Drive, Swiftwater, PA, 18370
Country 143504 0
United States of America
Phone 143504 0
+1 8006331610
Fax 143504 0
Email 143504 0
[email protected] (preferred)

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.